Fondazione Italiana Linfomi - Ets

This study is for people with a type of blood cancer called follicular lymphoma that has returned after treatment. It compares two maintenance therapies after initial chemo: one uses a single drug (rituximab), the other uses a combination of two drugs (rituximab and lenalidomide,…

This study tests adding romidepsin to standard chemotherapy (CHOEP) in young adults (ages 18-65) with newly diagnosed peripheral T-cell lymphoma. The goal is to see if this combination is safe and effective before a stem cell transplant. About 89 participants will receive the tre…

This study compares a shortened chemotherapy regimen combined with immunotherapy to the standard full-length treatment for people with newly diagnosed, advanced follicular lymphoma that has a high tumor burden. About 605 participants will be randomly assigned to either the shorte…

This study tests whether adding ibrutinib to standard chemotherapy (R-CHOP) helps people with a specific, aggressive type of lymphoma (ABC-DLBCL) who have a poor prognosis. About 75 adults under 65 will receive the combination for 6 cycles, then take ibrutinib alone for 18 months…

This study watches 212 people with Waldenström's macroglobulinemia who took zanubrutinib in Italy, either through a special access program or after the drug was approved. Researchers will track side effects and how long people stay on treatment. The goal is to see how well the dr…

This study examines stored tissue samples from 160 people with mantle cell lymphoma whose cancer came back or didn't respond to initial chemotherapy and rituximab. Researchers will analyze the samples to identify genetic and cellular features linked to treatment resistance. The g…

This study reviews the medical records of 241 adults who developed PTLD after an organ or stem cell transplant. The goal is to understand patient survival, identify common features of the disease, and see how different treatments are currently used. By learning from past cases, r…